Drug intelligence / Profile preview

Amara drops

Development stage: Phase 4
Lead developer: Weleda
Modality: Small Molecules
Administration: Oral

Overview

Amara drops (also known as Amara tincture) is a multi-herbal ethanolic solution manufactured by Weleda AG, traditionally used for digestive disorders and currently being investigated for functional dyspepsia. The preparation consists of nine plant extracts: Artemisia absinthium, Centaurium erythraea, Cichorium intybus, Gentiana lutea, Juniperus communis, Achillea millefolium, Peucedanum ostruthium, Salvia officinalis, and Taraxacum. Its primary mechanism of action involves the inhibition of M2 muscarinic receptors, which facilitates gastric fundus relaxation and improves gastric motility. It is indicated for symptoms such as bloating, nausea, loss of appetite, and heartburn.

Brand names: Weleda Amara-DropsAmara-Tropfen
Other names: Amara tinctureAmara

Targets

CHRM2 (M2)

Beyond the preview

Go deeper on Amara drops.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amara drops.

Explore the full profile